MADRID, April 24, 2017 /PRNewswire/ --
PharmaMar (MCE: PHM), a leading biopharmaceutical company focused on the discoveryand development of innovative marine-derived anticancer drugs, will host today a Research and Development Event in New York from 10:30 am - 1:30 pm ET.
PharmaMar´s senior management team and expert speakers will discuss scientific pipeline including; Phase 3 pivotal study with lurbinectedin (PM1183), current and prospective clinical trials, small-cell lung cancer and hereditary breast cancers, and an overview of Company strategy.
The presentation will be webcast simultaneously on the calendar section of the Company's Events Calendar page of the website at http://www.pharmamar.com and the slides will be posted there too.
A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the Events Calendar page of the company's website at http://www.pharmamar.com.
Expert guest speakers to include:
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.
Contact: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All